Candidate gene studies have often been focused on the role of dopamine receptors and related genes (namely DRD1, DRD2, DRD3, DRD4, and DRD5) as modulators of antipsychotic drug responsiveness and schizophrenia symptoms. The gene discussed is DRD3; the disease is schizophrenia.